SANA BIOTECHNOLOGY INC. - COMMON STOCK

Sana Biotechnology Announces FDA Clearance of Investigational New Drug Application for SC262, a Hypoimmune-modified, CD22-directed Allogeneic CAR T Therapy, for Patients with Relapsed or Refractory B-cell Malignancies

05 1 2024 08:00:00 提供 Nasdaq GlobeNewswire

Sana Biotechnology to Present at the 42nd Annual J.P. Morgan Healthcare Conference

03 1 2024 15:05:00 提供 Nasdaq GlobeNewswire

Sana Biotechnology Highlights Preclinical Data Supporting Tumor Control and Immune Evasion Capabilities of Hypoimmune-Modified Allogeneic CAR T Cells in Presentations at the American Society of Hematology Annual Meeting

11 12 2023 08:00:00 提供 Nasdaq GlobeNewswire

Sana Biotechnology Publishes Early Clinical Data Showing that SC291, a CD19-directed Allogeneic CAR T Therapy, Evades Immune Detection in Presence of Intact Immune System

01 12 2023 15:05:35 提供 Nasdaq GlobeNewswire

Sana Biotechnology to Present at November and December 2023 Investor Conferences

21 11 2023 08:00:00 提供 Nasdaq GlobeNewswire

Uppsala University Hospital and Sana Biotechnology Announce Authorization of the First-in-Human Clinical Trial Application for a Primary Islet Cell Treatment for Patients with Type 1 Diabetes

17 11 2023 08:00:00 提供 Nasdaq GlobeNewswire

Sana Biotechnology Announces FDA Clearance of Investigational New Drug Application for SC291, a Hypoimmune-modified, CD19-directed Allogeneic CAR T Therapy, for Patients with Lupus Nephritis, Extrarenal Lupus, and ANCA-associated Vasculitis

09 11 2023 15:05:00 提供 Nasdaq GlobeNewswire

Sana Biotechnology Reports Third Quarter 2023 Financial Results and Business Updates

08 11 2023 15:05:01 提供 Nasdaq GlobeNewswire

Sana Biotechnology Announces Five Presentations at the 65th American Society of Hematology Annual Meeting

02 11 2023 08:05:00 提供 Nasdaq GlobeNewswire

Sana Biotechnology Announces Increased Focus on Hypoimmune-Related Pipeline with the Potential to Deliver Clinical Proof of Concept Data from Four Programs in 2023 and 2024 with a 2024 Operating Burn under $200M

10 10 2023 15:15:00 提供 Nasdaq GlobeNewswire

Sana Biotechnology to Present at September 2023 Investor Conferences

30 8 2023 15:05:00 提供 Nasdaq GlobeNewswire

Sana Biotechnology Reports Second Quarter 2023 Financial Results and Business Updates

03 8 2023 15:05:01 提供 Nasdaq GlobeNewswire

Sana Biotechnology Highlights Preclinical Data from Hypoimmune and Fusogen Platforms at the International Society for Stem Cell Research (ISSCR) 2023 Annual Meeting

16 6 2023 08:00:00 提供 Nasdaq GlobeNewswire

Sana Biotechnology to Present at June 2023 Investor Conferences

31 5 2023 15:05:00 提供 Nasdaq GlobeNewswire

Sana Biotechnology Announces Preclinical Data Published in Nature Biotechnology Demonstrating its Hypoimmune-Engineered Cells Escape Immune Detection and Survive While Remaining Fully Functional

08 5 2023 15:35:00 提供 Nasdaq GlobeNewswire

Sana Biotechnology Reports First Quarter 2023 Financial Results and Business Updates

08 5 2023 15:05:01 提供 Nasdaq GlobeNewswire

Sana Biotechnology to Present at May 2023 Investor Conferences

03 5 2023 15:05:01 提供 Nasdaq GlobeNewswire

Sana Biotechnology Announces the Acceptance of Six Abstracts for Presentation at the American Society of Gene and Cell Therapy (ASGCT) 26th Annual Meeting

02 5 2023 15:30:00 提供 Nasdaq GlobeNewswire

Sana Biotechnology to Host Research & Development Day

24 4 2023 15:06:02 提供 Nasdaq GlobeNewswire

Sana Biotechnology Highlights Preclinical Hypoimmune Data for its Allogeneic CAR T Platform and Advancements with its In Vivo Fusogen Platform with Four Presentations at the 2023 AACR Annual Meeting

19 4 2023 15:05:00 提供 Nasdaq GlobeNewswire